Colorado's Partnership to Implement Evidence-Based Interventions to Reduce the Cancer Burden

科罗拉多州合作实施循证干预措施以减少癌症负担

基本信息

  • 批准号:
    10409393
  • 负责人:
  • 金额:
    $ 15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2022-01-31
  • 项目状态:
    已结题

项目摘要

Abstract The University of Colorado Cancer Center (UCCC) and the Colorado Cancer Coalition (CCC) will collaborate to develop regional networks to implement cancer control interventions to reduce cancer disparities in Colorado. UCCC’s catchment area is the State of Colorado and is the only NCI-designated cancer center in the state driving cancer discovery and innovation through its basic to translational to clinical to population science investigations. The CCC is a statewide organization seeking to eliminate the cancer burden in Colorado by engaging, facilitating, expanding, and strengthening the statewide network dedicated to improving Colorado lives touched by cancer. As leaders in the state, the UCCC and CCC will bring key stakeholders from 5 regions in Colorado (Front Range, Eastern, Western, Central Mountain, and the San Luis Valley/Southern regions) to partner and meaningfully reduce the incidence, mortality, and late-stage cancers that disproportionately affect underserved populations. Coloradans affected by cancer disparities would benefit greatly from increased access and uptake cancer control evidence-based interventions (EBIs) across the cancer continuum, but specially to reduce modifiable risk factors (e.g., smoking, human papillomavirus infection, low cancer screenings). Strengthening networks of community stakeholders from primary care and public health holds great promise for the wider implementation of evidence- based interventions and to increase cancer control research in Colorado. Thus, we will convene and support 5 RCNs to build collaboration and the infrastructure needed to bolster cancer control efforts. We have determined cancer disparity counties’ needs and capacity to implement cancer control activities and to conduct research. As the next step, UCCC and CCC will convene the 5 RCNs of key stakeholders to begin planning and implementing cancer control EBIs in disparity counties and to conduct research to study the implementation of EBIs. Each network will have a Regional Planner, an individual or organization, who will oversee the implementation and the short (1-year) and long-term (5-years) evaluation of the initiatives. The planner will also coordinate regional representation in the Colorado Cancer Coalition’s Cancer Task Forces to expand the referral resources and connect smaller regions of the state to the broader coalition efforts towards decreasing the state’s cancer burden. For the second aim, the RCNs will collaborate with UCCC investigators to conduct a pilot project to study the implementation of EBIs relevant to the regional cancer priorities and to affect cancer control targets such as improving HPV vaccine rates, lung cancer screenings, and colonoscopies, among other targets. The projects proposed will use a combination of conceptual frameworks to study the implementation of EBIs, including the Reach, Effectiveness, Adoption, and Implementation, Maintenance (RE-AIM) framework, the Practical Robust Implementation and Sustainability Model (PRISM), and the Consolidated Framework for Research (CFIR), which aid in designing and evaluating the implementation of EBIs to improve the cancer control outcomes targeted.
抽象的 科罗拉多大学癌症中心(UCCC)和科罗拉多州癌症联盟(CCC)将合作 开发区域网络以实施癌症控制干预措施,以减少科罗拉多州的癌症差异。 UCCC的集水区是科罗拉多州,是该州唯一的NCI指定癌症中心 通过其基本到临床转化为人口科学调查的癌症发现和创新。 CCC是一个旨在通过参与,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促进,促面, 扩展并加强全州网络,致力于改善科罗拉多州的癌症感动。 作为该州的领导人,UCCC和CCC将带来来自科罗拉多州5个地区的主要利益相关者(前排, 东部,西部,中央山和圣路易斯山谷/南部地区),有意义 减少对服务不足的人群不成比例的事件,死亡率和后期癌症。 受癌症差异影响的科罗拉多人将受益于增加的获取和摄取癌症控制 整个癌症的循证干预措施(EBI)仍在继续,但特别是为了减少可改变的危险因素 (例如,吸烟,人乳头瘤病毒感染,低癌症筛查)。加强社区网络 来自初级保健和公共卫生的利益相关者对更广泛的证据实施了巨大的希望 - 基于干预措施并增加科罗拉多州的癌症控制研究。那,我们将方便和支持5 RCN建立协作和加强癌症控制工作所需的基础设施。我们已经确定 癌症差异县的需求和能力实施癌症控制活动和进行研究。作为 下一步,UCCC和CCC将召集主要利益相关者的5个RCN开始计划和实施 癌症控制EBI在差异县并进行研究以研究EBIS的实施。每个 网络将拥有一个区域规划师,一个个人或组织,他们将监督实施和 对计划的短期(1年)和长期(5年)评估。计划者还将协调区域 在科罗拉多州癌症联盟的癌症工作队中的代表,以扩大推荐资源和 将该州的较小地区与更广泛的联盟努力联系起来,以减少该州的癌症伯恩。 为了第二个目标,RCN将与UCCC调查人员合作进行试点项目,以研究该项目 EBI与区域癌症优先级相关的EBIS,并影响癌症控制目标,例如 改善HPV疫苗率,肺癌筛查和结肠镜检查等。项目 拟议的将使用概念框架的组合来研究EBI的实施,包括 覆盖,有效性,采用和实施,维护(RE-AIM)框架,实用性 实施和可持续性模型(PRISM)以及研究的合并框架(CFIR),该框架 协助设计和评估EBI的实施,以改善针对的癌症控制结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

RICHARD D SCHULICK的其他基金

University of Colorado Cancer Center Support Grant
科罗拉多大学癌症中心支持补助金
  • 批准号:
    10371494
    10371494
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
University of Colorado Cancer Center Support Grant - CTRAC Supplement Yr 02
科罗拉多大学癌症中心支持补助金 - CTRAC 补充第 02 年
  • 批准号:
    10439981
    10439981
  • 财政年份:
    2021
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Interferon Signaling and the Differential Malignancy Spectrum of Down Syndrome
干扰素信号转导和唐氏综合症的鉴别恶性肿瘤谱
  • 批准号:
    9933418
    9933418
  • 财政年份:
    2019
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
  • 批准号:
    6988218
    6988218
  • 财政年份:
    2005
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
  • 批准号:
    7228884
    7228884
  • 财政年份:
    2005
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
  • 批准号:
    7085533
    7085533
  • 财政年份:
    2005
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
  • 批准号:
    7406622
    7406622
  • 财政年份:
    2005
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Listeria Monocytogenes to Treat Hepatic Metastases
单核细胞增生李斯特菌治疗肝转移
  • 批准号:
    7590470
    7590470
  • 财政年份:
    2005
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
GM-CSF Enhanced Colorectal Cancer Tumor Vaccine Program
GM-CSF增强型结直肠癌肿瘤疫苗计划
  • 批准号:
    6945464
    6945464
  • 财政年份:
    2004
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
GM-CSF Enhanced Colorectal Cancer Tumor Vaccine Program
GM-CSF增强型结直肠癌肿瘤疫苗计划
  • 批准号:
    7477966
    7477966
  • 财政年份:
    2004
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:

相似海外基金

Characterizing the genetic etiology of delayed puberty with integrative genomic techniques
利用综合基因组技术表征青春期延迟的遗传病因
  • 批准号:
    10663605
    10663605
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
  • 批准号:
    10643145
    10643145
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System
ACTS(AD 临床试验模拟):为阿尔茨海默病临床试验模拟系统开发先进的信息学方法
  • 批准号:
    10753675
    10753675
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Unraveling how Lipophilic Modulators Alter pLGIC Function via Interactions with the M4 Transmembrane Helix
揭示亲脂性调节剂如何通过与 M4 跨膜螺旋相互作用改变 pLGIC 功能
  • 批准号:
    10785755
    10785755
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别:
Testing Approaches to Promote Breast Cancer Screening in Rural Ghana
促进加纳农村地区乳腺癌筛查的测试方法
  • 批准号:
    10645446
    10645446
  • 财政年份:
    2023
  • 资助金额:
    $ 15万
    $ 15万
  • 项目类别: